Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects

NCT00170456 is registered in ClinicalTrials.gov with PharmAthene UK Limited as lead sponsor.

NCT NCT00170456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00170456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects
Lead sponsor
PharmAthene UK Limited
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
February 28, 2007
Enrollment
415 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of bacillus anthracis (anthrax) infection